The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

Health tech firm Datavant has reached an agreement to acquire Aetion, a specialist in real-world evidence (RWE), pooling ...

Join the 4th Process Development for Cell Therapies Summit to hear from 24+ industry leaders from biopharma and service ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

Changes to Health Technology Assessment (HTA) in Europe offer new opportunities to streamline processes and get innovative ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...

The infant was born with a metabolic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, in which the ...

That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid ...

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

However, trust gaps among clinicians and patients are threatening to slow the adoption and impact of AI. Among HCPs, ...